Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity Disclosure (Details)

Stockholders' Equity Disclosure (Details) (USD $)	12 Months Ended		1 Months Ended			9 Months Ended
Stockholders' Equity Disclosure (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	May 31, 2014	Jan. 31, 2014	Aug. 30, 2013	Sep. 30, 2014	Oct. 02, 2014	Oct. 31, 2013	Jun. 21, 2013
Common stock authorized	20,000,000us-gaap_CommonStockSharesAuthorized	20,000,000us-gaap_CommonStockSharesAuthorized
Common shares issued	9,495,045us-gaap_CommonStockSharesIssued	8,082,000us-gaap_CommonStockSharesIssued
Common shares outstanding	10,952,356us-gaap_CommonStockSharesOutstanding	8,082,000us-gaap_CommonStockSharesOutstanding
Proceeds from common stock issuance	$ 366,324
Common stock issued	209,324
Common stock issued for Preferred stock conversion	1,207,491
Common stock issued for debt conversion	1,100,876
Preferred stock authorized	4,500,000us-gaap_PreferredStockSharesAuthorized	4,500,000us-gaap_PreferredStockSharesAuthorized
Preferred stock outstanding	178,924us-gaap_PreferredStockSharesOutstanding	1,005,648us-gaap_PreferredStockSharesOutstanding
Number of options granted	298,000	410,000
Stock-based compensation expense	231,524	216,083
Unrecognized compensation expense	308,041fil_UnrecognizedCompensationExpense	404,006fil_UnrecognizedCompensationExpense
Common Stock Equity
Units offered (Common Stock and Warrants)							3,650,807
Units offered (Common Stock and Warrants), price per unit							$ 1.75
Series A Preferred Stock
Preferred shares converted to common shares		600,000
Annual dividend rate		$ 0.066664
Series B Preferred Stock
Preferred shares converted to common shares	177,000	1,323,000
Annual dividend rate	$ 0.16
Accumulated dividends released	40,529	361,426
Series C Preferred Stock
Preferred shares converted to common shares	101,000	659,000
Preferred Series C
Preferred stock authorized	760,000	760,000
Accumulated dividends released	24,869	95,600
Series D Preferred Stock
Units offered (Common Stock and Warrants)								772,352	1,500,000
Units offered (Common Stock and Warrants), price per unit								$ 3.00	$ 3.00
Annual dividend rate	$ 0.24
Shares outstanding	178,924	727,648
Units offered (Common Stock and Warrants), potential proceeds								2,317,056	4,500,000
Units sold during offering			118,655	53,332	727,648
Gross proceeds from units sold in offering			355,967	159,996	2,182,944
Units offered (Common Stock and Warrants), additional over-allotment								1,000,000
Units offered (Common Stock and Warrants), potential proceeds for additional over-allotment								3,000,000
Dividends paid	177,846	24,407
Dividends payable	45,590
Original issue price per share	$ 3.00
Beneficial conversion feature (BCF)	$ 24,279	$ 176,729
2011 Equity Incentive Plan, January 13, 2014
Number of options granted	94,000
2011 Equity Incentive Plan, January 16, 2014
Number of options granted	40,000
2011 Equity Incentive Plan, February 1, 2014
Number of options granted	50,000
2011 Equity Incentive Plan, April 4, 2014
Number of options granted	4,000
2011 Equity Incentive Plan, June 19, 2014
Number of options granted						10,000
2011 Equity Incentive Plan, June 19, 2014 (2)
Number of options granted						100,000
Series D Unit offering
Number of warrants issued	85,993
Non-public offering of notes and warrants
Number of warrants issued	283,329
Non-public offering of notes and warrants(2)
Number of warrants issued	432,995
Private equity offering
Number of warrants issued	104,659
Conversion of unsecured notes payable
Number of warrants issued	550,438
Conversion of Series D preferred shares
Number of warrants issued	603,742